By all accounts 2018 was a sensational year for Food and Drug Administration (FDA) approvals of new drugs and biologics. But, payers are faced with the prospect of having to manage the impact of drugs launching at increasingly higher prices.
FDA’s Banner Year For Approvals: Will Market Access To New Drugs Follow Suit?
